. "Cephalotaxus alkaloid"@en . . . . . . . . . . . . . . . "omacetaxine mepesuccinate"@en . " "@en . . "Homoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis. "@en . . . . . . . . "Plasma protein binding is equal or less than 50%."@en . . "Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. "@en . . "CGX-635"@en . . "The most severe adverse effects after homoharringtonine administration are myelosuppression, bleeding, hyperglycemia, and fetal harm."@en . "26833-87-4"@en . "Myelostat"@en . . "Homoharringtonine has a half life of about 6 hours after subcutaneous administration."@en . "HHT"@en . "Homoharringtonine"@en . "Yaguang Liu, \"Process for producing harringtonine and homoharringtonine.\" U.S. Patent US4783454, issued June, 1980."@en . . "The main route of elimination for homoharringtonine is still unknown, but renal elimination is less than 15%."@en . "Homoharringtonine, AKA HHT or omacetaxine mepesuccinate, is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Homoharringtonine is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, homoharringtonine received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, homoharringtonine received Orphan Drug status from the FDA for the treatment of CML. In November 2006, homoharringtonine, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, homoharringtonine was marketed under the brand name Synribo\u2122 and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. "@en . . . . . "Humans and other mammals"@en . "# Lou YJ, Qian WB, Jin J: Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma. 2007 Jul;48(7):1400-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17613769 # Jie H, Donghua H, Xingkui X, Liang G, Wenjun W, Xiaoyan H, Zhen C: Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma. 2007 May;48(5):964-77. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17487741 # FDA label."@en . "Homoharringtonine absorption was not quantified, but maximum concentration is reached after about 30 mins. "@en . . . "Clearance for homoharringtonine was not quantified."@en . . "approved"@en . . "Homoharringtonine has a steady state Vd of 141 \u00B1 93.4 L."@en . . . . . "Homoharringtonine is administered subcutaneously, so food should have no effects. "@en .